Home » Stocks » BTHE

Boston Therapeutics Inc. (BTHE)

Stock Price: $0.0298 USD -0.0002 (-0.67%)
Updated Mar 5, 2021 3:37 PM EST - Market closed
Market Cap 3.31M
Revenue (ttm) 11,462
Net Income (ttm) -2.71M
Shares Out 111.13M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $0.0298
Previous Close $0.0300
Change ($) -0.0002
Change (%) -0.67%
Day's Open 0.0387
Day's Range 0.0298 - 0.0387
Day's Volume 25,499
52-Week Range 0.0055 - 0.06

News

There are no news available yet.

About BTHE

Boston Therapeutics, a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical tr... [Read more...]

Industry
Biotechnology
Founded
2009
CEO
Chi-Heng Cheng
Stock Exchange
OTCMKTS
Ticker Symbol
BTHE
Full Company Profile

Financial Performance

In 2019, BTHE's revenue was $16,329, a decrease of -48.53% compared to the previous year's $31,723. Losses were -$3.69 million, 2.58% more than in 2018.

Financial Statements